Document 2013
 DOCN  M94A2013
 TI    Transdominant and attenuated HIV-1s: implications for gene therapy.
 DT    9412
 AU    Jeang KT; Smith S; Huang LM; NIAID, NIH, Bethesda, MD.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):40 (abstract no. 132A). Unique
       Identifier : AIDSLINE ICA10/94370562
 AB    OBJECTIVE: To create altered HIV-1 proviruses, containing foreign genes,
       capable of autonomous replication with either a transdominant inhibitory
       phenotype or an attenuated phenotype for pathogenicity. METHODS: Four
       HIV-1 proviruses separately containing a PKR gene, an HSV-1 thymidine
       kinase gene, an HTLV-I Tax gene, and a ribozyme gene were created. These
       proviruses were tested in continuous T-lymphocyte cultures either alone
       or in co-cultivation with wildtype HIV-1 to assay for attenuated
       pathogenicity versus transdominant inhibitory properties. RESULTS: We
       have found that proviruses containing PKR, HSV tk, and ribozyme have
       capacities to be transdominant inhibitors of wildtype HIV-1. An altered
       HIV-1 containing HTLV-I Tax showed highly reduced pathogenicity in
       lymphocyte cultures. DISCUSSION: Attenuated HIVs are potentially useful
       vaccine candidates. Transdominant HIVs that in themselves have been
       constructed to be attenuated are useful for therapeutic considerations.
 DE    Cells, Cultured  *Gene Therapy  Genes, pX  Genes, Viral/GENETICS  Human
       HIV Infections/THERAPY  HIV-1/*GENETICS/*PATHOGENICITY  HTLV-I/GENETICS
       Protein-Serine-Threonine Kinases/GENETICS  Proviruses/*GENETICS
       T-Lymphocytes/MICROBIOLOGY  Thymidine Kinase/GENETICS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).